Drilldown: Medicines
Appearance
Medicines > onset
:
Postprandial glucose effect within days; HbA1c by 12 weeks
or
Symptom relief within 24-48 hours 
:
Postprandial glucose effect within days; HbA1c by 12 weeks
or
Symptom relief within 24-48 hours 
Use the filters below to narrow your results.
[[:Category:Anti-herpesvirus_agents|Anti-herpesvirus agent]] (1) ·
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (2) ·
[[:Category:Antivirals|Antiviral]] (1) ·
[[:Category:DPP-4_inhibitors|DPP-4 inhibitor]] (2) ·
[[:Category:Incretin_modulators|Incretin pathway modulator]] (2) ·
[[:Category:Nucleoside_analogs|Nucleoside analog (prodrug)]] (1)
None (1) ·
'"`UNIQ--vote-000005D0-QINU`"' Selectivity comes from the viral-kinase-only initial phosphorylation step, which is why uninfected cells generate minimal active drug'"`UNIQ--ref-000005D1-QINU`"'. Dose-adjust by renal function; rare crystalline nephropathy with rapid IV acyclovir. (1) ·
'"`UNIQ--vote-00000762-QINU`"' Largely renally cleared, hence the eGFR-tiered dosing. Rare but well-documented signals: acute pancreatitis (uncertain causal contribution), severe joint pain, and bullous pemphigoid (class effect, especially in older Asian patients)'"`UNIQ--ref-00000763-QINU`"'. (1)
Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Widely used in pregnancy when antiviral indicated; reassuring registry data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 3 results in range #1 to #3.

